BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 32665297)

  • 1. Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial.
    Uppaluri R; Campbell KM; Egloff AM; Zolkind P; Skidmore ZL; Nussenbaum B; Paniello RC; Rich JT; Jackson R; Pipkorn P; Michel LS; Ley J; Oppelt P; Dunn GP; Barnell EK; Spies NC; Lin T; Li T; Mulder DT; Hanna Y; Cirlan I; Pugh TJ; Mudianto T; Riley R; Zhou L; Jo VY; Stachler MD; Hanna GJ; Kass J; Haddad R; Schoenfeld JD; Gjini E; Lako A; Thorstad W; Gay HA; Daly M; Rodig SJ; Hagemann IS; Kallogjeri D; Piccirillo JF; Chernock RD; Griffith M; Griffith OL; Adkins DR
    Clin Cancer Res; 2020 Oct; 26(19):5140-5152. PubMed ID: 32665297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study.
    Harrington KJ; Kong A; Mach N; Chesney JA; Fernandez BC; Rischin D; Cohen EEW; Radcliffe HS; Gumuscu B; Cheng J; Snyder W; Siu LL
    Clin Cancer Res; 2020 Oct; 26(19):5153-5161. PubMed ID: 32669371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012.
    Mehra R; Seiwert TY; Gupta S; Weiss J; Gluck I; Eder JP; Burtness B; Tahara M; Keam B; Kang H; Muro K; Geva R; Chung HC; Lin CC; Aurora-Garg D; Ray A; Pathiraja K; Cheng J; Chow LQM; Haddad R
    Br J Cancer; 2018 Jul; 119(2):153-159. PubMed ID: 29955135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.
    Sacco AG; Chen R; Worden FP; Wong DJL; Adkins D; Swiecicki P; Chai-Ho W; Oppelt P; Ghosh D; Bykowski J; Molinolo A; Pittman E; Estrada MV; Gold K; Daniels G; Lippman SM; Natsuhara A; Messer K; Cohen EEW
    Lancet Oncol; 2021 Jun; 22(6):883-892. PubMed ID: 33989559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.
    Chow LQM; Haddad R; Gupta S; Mahipal A; Mehra R; Tahara M; Berger R; Eder JP; Burtness B; Lee SH; Keam B; Kang H; Muro K; Weiss J; Geva R; Lin CC; Chung HC; Meister A; Dolled-Filhart M; Pathiraja K; Cheng JD; Seiwert TY
    J Clin Oncol; 2016 Nov; 34(32):3838-3845. PubMed ID: 27646946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma.
    Wise-Draper TM; Gulati S; Palackdharry S; Hinrichs BH; Worden FP; Old MO; Dunlap NE; Kaczmar JM; Patil Y; Riaz MK; Tang A; Mark J; Zender C; Gillenwater AM; Bell D; Kurtzweil N; Mathews M; Allen CL; Mierzwa ML; Casper K; Jandarov R; Medvedovic M; Lee JJ; Harun N; Takiar V; Gillison M
    Clin Cancer Res; 2022 Apr; 28(7):1345-1352. PubMed ID: 35338369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma.
    Wang J; Sun H; Zeng Q; Guo XJ; Wang H; Liu HH; Dong ZY
    Sci Rep; 2019 Sep; 9(1):13404. PubMed ID: 31527697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial.
    Ferris RL; Spanos WC; Leidner R; Gonçalves A; Martens UM; Kyi C; Sharfman W; Chung CH; Devriese LA; Gauthier H; Chiosea SI; Vujanovic L; Taube JM; Stein JE; Li J; Li B; Chen T; Barrows A; Topalian SL
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
    Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ
    Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Neoadjuvant Pembrolizumab for Oral Cavity Squamous Cell Carcinoma With Adverse Events After Surgery in Treatment-Naive Patients.
    Tang AL; O'Neil T; McDermott S; Tripathi S; Tikhtman R; Mark JR; Patil Y; Tabangin M; Altaye M; Wise-Draper TM; Zender CA
    JAMA Otolaryngol Head Neck Surg; 2022 Oct; 148(10):935-939. PubMed ID: 36006622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
    Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
    Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
    Cohen EEW; Soulières D; Le Tourneau C; Dinis J; Licitra L; Ahn MJ; Soria A; Machiels JP; Mach N; Mehra R; Burtness B; Zhang P; Cheng J; Swaby RF; Harrington KJ;
    Lancet; 2019 Jan; 393(10167):156-167. PubMed ID: 30509740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.
    Saada-Bouzid E; Peyrade F; Guigay J
    Curr Opin Oncol; 2019 May; 31(3):146-151. PubMed ID: 30893146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
    Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Non-Small-Cell Lung Cancer and High PD-L1 Tumor Expression.
    Tambo Y; Sone T; Shibata K; Nishi K; Shirasaki H; Yoneda T; Araya T; Kase K; Nishikawa S; Kimura H; Kasahara K
    Clin Lung Cancer; 2020 Sep; 21(5):e366-e379. PubMed ID: 32199806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma.
    Kim CG; Hong MH; Kim D; Lee BH; Kim H; Ock CY; Kelly G; Bang YJ; Kim G; Lee JE; Kim C; Kim SH; Hong HJ; Park YM; Sim NS; Park H; Park JW; Lee CG; Kim KH; Park G; Jung I; Han D; Kim JH; Cha J; Lee I; Kang M; Song H; Oum C; Kim S; Kim S; Lim Y; Kim-Schulze S; Merad M; Yoon SO; Kim HJ; Koh YW; Kim HR
    Clin Cancer Res; 2024 May; 30(10):2097-2110. PubMed ID: 38457288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study.
    Powell SF; Gold KA; Gitau MM; Sumey CJ; Lohr MM; McGraw SC; Nowak RK; Jensen AW; Blanchard MJ; Fischer CD; Bykowski J; Ellison CA; Black LJ; Thompson PA; Callejas-Valera JL; Lee JH; Cohen EEW; Spanos WC
    J Clin Oncol; 2020 Jul; 38(21):2427-2437. PubMed ID: 32479189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
    Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
    Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical Study of PD-1/PD-L1 Axis Expression in Oral Tongue Squamous Cell Carcinomas: Effect of Neoadjuvant Chemotherapy on Local Recurrence.
    Naruse T; Yanamoto S; Okuyama K; Ohmori K; Tsuchihashi H; Furukawa K; Yamada SI; Umeda M
    Pathol Oncol Res; 2020 Apr; 26(2):735-742. PubMed ID: 30767115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial.
    Cohen EEW; Nabell L; Wong DJ; Day T; Daniels GA; Milhem M; Deva S; Jameson M; Guntinas-Lichius O; Almubarak M; Strother M; Whitman E; Chisamore M; Obiozor C; Bagulho T; Gomez-Romo J; Guiducci C; Janssen R; Gamelin E; Algazi AP
    Clin Cancer Res; 2022 Mar; 28(6):1157-1166. PubMed ID: 34965944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.